Results 141 to 150 of about 34,651 (222)

Perspectives on the Influence of Pharmaceutical and MedTech Companies on Deprescribing Decisions and Conference Sponsorship: A Survey Study

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 1, January 2026.
ABSTRACT Background The involvement and sponsorship of pharmaceutical and medical technology (MedTech) companies in deprescribing and medication optimization activities raise questions about conflicts of interest. We surveyed registrants and attendees of previous International Conferences on Deprescribing to explore views on the acceptability and ...
Katharina Tabea Jungo, Cynthia M. Boyd, Barbara Farrell, Caroline McCarthy   +3 more
wiley   +1 more source

“Sex‐Based Inequities in Post‐STEMI Secondary Prevention: A Critical Appraisal and Path Forward”

Clinical Cardiology, Volume 49, Issue 1, January 2026.
Ibadullah Tahir, Hunain Shahbaz
wiley   +1 more source

UK Biobank: Transforming drug discovery and precision medicine

British Journal of Pharmacology, Volume 183, Issue 2, Page 234-248, January 2026.
UK Biobank is a large‐scale, prospective study with extensive genetic and phenotypic data on half a million individuals. Volunteers, aged between 40 and 69 years, were recruited between 2006 and 2010 from the general population of the United Kingdom.
Jelena Bešević, Saredo Said, Reka Nagy, Yalda Jamshidi, Christopher D. Whelan, Lauren Carson, Martin K. Rutter, Adam J. Lewandowski, Mark Effingham, Rory Collins, Ben Lacey, Naomi E. Allen   +11 more
wiley   +1 more source

Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes (iNPHORM, United States)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 675-690, January 2026.
Abstract Aims Level 3 (severe) hypoglycaemia is a serious, yet preventable, complication of insulin‐ or secretagogue‐treated diabetes. However, real‐world insight into its incidence and risk factors remains limited. We analysed data from the iNPHORM study to address this gap.
Alexandria Ratzki‐Leewing, Jason E. Black, Jasminder Bhatti, Bridget L. Ryan, Guangyong Zou, Yu Kuei Lin, Shuo J. Huang, Rozalina G. McCoy, Stewart B. Harris   +8 more
wiley   +1 more source

Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Long‐term treatment with agalsidase alfa in 1864 adults with Fabry disease in the Fabry Outcome Survey confirmed previously reported beneficial effects on renal function and cardiomyopathy. Over a median (min, max) of 6.0 (0, 21.6) years of treatment, annualized changes in eGFR remained relatively stable in females and declined slightly in males.
Derralynn A. Hughes, Guillem Pintos‐Morell, Christoph Kampmann, Christina Anagnostopoulou, Jaco Botha, Siddharth Jain, Kathleen Nicholls, Dau‐Ming Niu, Ricardo Reisin, Michael L. West, Jörn Schenk, Uma Ramaswami, Roberto Giugliani   +12 more
wiley   +1 more source

A Real‐World Study on the Characteristics, Treatment Patterns, and Healthcare Resource Utilization in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Systemic Treatment in China

Dermatologic Therapy, Volume 2026, Issue 1, 2026.
Background Psoriasis is an immune‐mediated skin disease, of which plaque psoriasis is the predominant form. This study aimed to understand the clinical characteristics of patients with moderate‐to‐severe plaque psoriasis who received systemic medications in a real‐world setting in China.
Beibei Zhu, Meifang Wang, Lina Ba, Joe Zhuo, Linfeng Li, Xueyuan Yang, Suraiya Saleem   +6 more
wiley   +1 more source

Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). [PDF]

Pharmacoepidemiol Drug Saf
Kurz X, Cohet C, Perez-Gutthann S, Rao S, Gardarsdottir H.   +4 more
europepmc   +1 more source

Suitability of Japanese Medical Databases for Studies on Infant Outcomes After Maternal Drug Exposure: An Evaluation Based on Core Data Elements. [PDF]

Pharmacoepidemiol Drug Saf
Hatakeyama S, Sakai T, Tsuchiya M, Kikuchi D, Sato Y, Kondo Y, Sato I, Okada Y, Obara T.   +8 more
europepmc   +1 more source

The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE-D) ISPE-Endorsed Guidance. [PDF]

Pharmacoepidemiol Drug Saf
Hayes KN, Niznik JD, Gnjidic D, Moriarty F, Bennett D, Laroche ML, Talbot D, Alcusky M, Sessa M, Coe AB, Sirois C, Zullo AR, Li X, Chalasani SH, Syed J, Sawan M, Moga DC.   +16 more
europepmc   +1 more source

Re: "the challenges of measuring socioeconomic inequality in pharmacoepidemiology studies". [PDF]

Am J Epidemiol
Wi CI, Shim D, Juhn YJ.
europepmc   +1 more source